Changes in blood lipid levels and influencing factors among treatment-na?ve adult male HlV/AlDS patients following BlC/FTC/TAF vs. 3TC+EFV+TDF
10.1097/CM9.0000000000003147
- VernacularTitle:Changes in blood lipid levels and influencing factors among treatment-na?ve adult male HlV/AlDS patients following BlC/FTC/TAF vs. 3TC+EFV+TDF
- Author:
Xi WANG
1
;
An LIU
;
Zaicun LI
;
Hongwei ZHANG
;
Esther Ruojun WU
;
Ying SHAO
;
Jianwei LI
;
Jiangzhu YE
;
Wei LIU
;
Lijun SUN
Author Information
1. Clinic of Center for Infection, Beijing Youan Hospital, Capital Medical University, Beijing 100069, China
- Keywords:
Antiretroviral therapy;
Blood lipids;
Bictegravir/emtricitabine/tenofovir alafenamide;
Lamivudine, efavirenz, and tenofovir disoproxil fumarate;
BIC/FTC/T
- From:
Chinese Medical Journal
2024;137(12):1447-1452
- CountryChina
- Language:Chinese
-
Abstract:
Background::Antiretroviral therapy (ART) was often associated with dyslipidemia among human immunodeficiency virus (HIV)/acquired immunodeficiency syndrome (AIDS) patients. This study aimed to assess treatment-na?ve adult male patients with HIV/AIDS who initiated ART with either co-formulated bictegravir, emtricitabine, and tenofovir alafenamide (BIC/FTC/TAF) or lamivudine, efavirenz, and tenofovir disoproxil fumarate (3TC+EFV+TDF), monitoring at weeks 4, 12, 24, and 48.Methods::A case-control retrospective study was conducted. The newly diagnosed HIV-infected individuals attending the sexual transmission disease (STD)/AIDS clinic of Beijing Youan Hospital, Capital Medical University, from January to December 2021. The patients were divided into BIC/FTC/TAF group or 3TC+EFV+TDF group. High-density lipoprotein cholesterol (HDL-C), low-density lipoprotein cholesterol (LDL-C), triglyceride (TG), and total cholesterol (TC) at different time points over 48 weeks between two groups were compared. A multivariate Cox regression model was used to identify relevant influencing factors for the population at high risk of increased LDL-C.Results::A total of 870 participants, with 510 in BIC/FTC/TAF group and 360 in 3TC+EFV+TDF group. There were no statistically significant differences in median age, baseline CD4/CD8 ratio, median body mass index (BMI) between the two groups. In both two groups, levels of TG, TC, and LDL-C were higher at 4 weeks, 12 weeks, and 24 weeks of treatment (all P <0.05), and there were no statistically significant differences at 48 weeks compared to those at baseline (all P >0.05). In addition, the differences in average changes of the level of TG, TC, HDL-C, and LDL-C from weeks 4, 12, 24, and 48 to baseline between two groups were not statistically significant (all P >0.05). Multivariate Cox proportional risk model analysis showed that initiating ART with HIV RNA ≥10 5 copies/mL (compared with <10 5 copies/mL) was associated with an increased risk of elevated LDL-C (hazard ratio = 1.26, 95% confidence interval: 1.07-1.48, P = 0.005). Conclusions::Transient elevations in blood lipid levels (TC, TG, HDL-C, and LDL-C) were observed in treatment-na?ve adult male HIV/AIDS patients with BIC/FTC/TAF at 4 weeks, 12 weeks, and 24 weeks of treatment. However, these levels did not differ significantly from baseline after 48 weeks of treatment, regardless of whether patients were in the BIC/FTC/TAF or 3TC+EFV+TDF group.
